Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health Receives FDA Fast Track Designation for Elacestrant (RAD1901)
- Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018 - - Phase 2 Study is a potentially pivotal trial for accelerated approval - WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc.
View HTML
Toggle Summary Radius Health to Present First Health Economics Data on TYMLOS™ (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017
Five posters will cover new data on the need for osteoporosis awareness as well as cost-effectiveness data on treatment with TYMLOS WALTHAM, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing and
View HTML
Toggle Summary Radius Health to Announce Third Quarter 2017 Financial Results, Host Conference Call and Live Webcast on November 2, 2017
WALTHAM, Mass., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company will host a conference call and live audio webcast at 4:30 p.m.
View HTML
Toggle Summary Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer
Study will evaluate safety, dose and tumor response in postmenopausal women with metastatic disease
View HTML
Toggle Summary Radius Health to Present at Cantor Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today
View HTML
Toggle Summary Radius Health Presents Positive Data for TYMLOS™ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting
ACTIVExtend trial demonstrated statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by alendronate WALTHAM, Mass., Sept. 10, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to
View HTML
Toggle Summary Radius Health to Present at Morgan Stanley 15th Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today
View HTML
Toggle Summary Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS™ (abaloparatide) Injection
Results from the ACTIVExtend trial, which demonstrated statistically significant fracture risk reduction at 3.5 years of sequential therapy — TYMLOS followed by alendronate — will be presented in an Oral Plenary Session             Company plans to submit the ACTIVExtend results to the FDA by year
View HTML
Toggle Summary New National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures
Joint Survey from National Osteoporosis Foundation, HealthyWomen and Radius Health Sounds an Urgent Call to Action for Women to Know Their Risk, Get the Facts ‘Fractured Truth' Education Campaign Addresses Entrenched Misperceptions, Asks Women to Rethink Their Beliefs About Bone Health WALTHAM,
View HTML
Toggle Summary Radius Health Announces Pricing of $300 Million of 3.00% Convertible Senior Notes due 2024
WALTHAM, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the pricing of $300 million aggregate principal amount of 3.00% Convertible Senior Notes due 2024 (the "notes") in an underwritten public offering (the "offering")
View HTML